Your browser doesn't support javascript.
loading
Use of omalizumab is associated with improvement of pruritic skin disorders induced by immune checkpoint inhibitors: A retrospective cohort from the European Task Force of Dermatology for Cancer patients.
Alamon-Reig, Francesc; Bosch-Amate, Xavier; Giavedoni, Priscila; Nikolaou, Vasiliki; Mangas, Cristina; Apalla, Zoe; Mayor, Ander; Oikonomou, Chrysa; Starace, Michela; Sibaud, Vincent; Carrera, Cristina.
Affiliation
  • Alamon-Reig F; Department of Dermatology, Hospital Clínic de Barcelona, FRCB, Universitat de Barcelona, Barcelona, Spain.
  • Bosch-Amate X; Department of Dermatology, Hospital Clínic de Barcelona, FRCB, Universitat de Barcelona, Barcelona, Spain.
  • Giavedoni P; Department of Dermatology, Hospital Clínic de Barcelona, FRCB, Universitat de Barcelona, Barcelona, Spain.
  • Nikolaou V; DermatoOncology Department, Andreas Sygros Hospital, University of Athens, Athens, Greece.
  • Mangas C; Dermatology and Oncology Department, Istituto Oncologico Svizzera Italiana (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
  • Apalla Z; Second Department of Dermatology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Mayor A; Servicio de Dermatología, Hospital Universitario La Paz, Madrid, Spain.
  • Oikonomou C; Dermatology Department, General University Hospital of Patra, Patra, Greece.
  • Starace M; Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Sibaud V; Departments of Oncodermatology and Clinical Research, Oncopole Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
  • Carrera C; Department of Dermatology, Hospital Clínic de Barcelona, FRCB, Universitat de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: ccarrera@clinic.cat.
J Am Acad Dermatol ; 90(2): 429-432, 2024 Feb.
Article in En | MEDLINE | ID: mdl-37844688

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Diseases / Dermatology / Neoplasms Limits: Humans Language: En Journal: J Am Acad Dermatol Year: 2024 Document type: Article Affiliation country: Spain Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Diseases / Dermatology / Neoplasms Limits: Humans Language: En Journal: J Am Acad Dermatol Year: 2024 Document type: Article Affiliation country: Spain Country of publication: United States